<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7262202\results\search\testTrace\results.xml">
  <result pre="10.1111/1759-7714.13424TCA13424 : Clinical Guideline: Clinical Guideline Recommendations of individualized medical" exact="treatment" post="and common adverse events management for lung cancer patients"/>
  <result pre="lung cancer patients during the outbreak of COVIDâ€�19 epidemic Individualized" exact="treatment" post="for lung cancer Z. Zhao et al. ZhaoZhe939662016@qq.com1BaiHua1DuanJianchun1WangJiehttps://orcid.org/0000-0002-5602-04871zlhuxi@163.com[1], Department"/>
  <result pre="during cancer treatment. It is necessary to provide individualized medical" exact="treatment" post="and management of treatmentâ€�related adverse events for patients with"/>
  <result pre="conditions and regional epidemic patterns into consideration, providing appropriate individualized" exact="treatment" post="strategies for lung cancer patients with different stages is"/>
  <result pre="this article aims to provide recommendations and suggestions of individualized" exact="treatment" post="strategies and management of common adverse events for patients"/>
  <result pre="cross infection, which has obviously affected the routine examination and" exact="treatment" post="of lung cancer patients in regions affected by the"/>
  <result pre="some advanced lung cancer patients need to receive regular antitumor" exact="treatment" post="due to the high tumor burden and deal with"/>
  <result pre="on lung cancer patients, providing recommendations of scientific and reasonable" exact="treatment" post="and preventive measures for lung cancer patients in the"/>
  <result pre="the characteristics of lung cancer, this article focuses on individualized" exact="treatment" post="recommendations and measures for adverse events management during the"/>
  <result pre="for adverse events management during the COVIDâ€�19 epidemic. Prevention of" exact="infection" post="is paramount Due to low immunity combined with poor"/>
  <result pre="problems and deal with them promptly.4 Recommendations of individualized medical" exact="treatment" post="strategies Lung cancer patients awaiting treatment For lung cancer"/>
  <result pre="Recommendations of individualized medical treatment strategies Lung cancer patients awaiting" exact="treatment" post="For lung cancer patients who have not yet started"/>
  <result pre="cancer patients who have not yet started medical treatment, the" exact="treatment" post="strategy should be comprehensively considered according to the tumor"/>
  <result pre="receptor (EGFR) gene mutations, oral EGFR tyrosine kinase inhibitor (EGFRâ€�TKI)" exact="treatment" post="at home may be considered as the optional adjuvant"/>
  <result pre="treatment at home may be considered as the optional adjuvant" exact="treatment" post="option,6 which may reduce the risk of cross infection"/>
  <result pre="adjuvant treatment option,6 which may reduce the risk of cross" exact="infection" post="caused by repeated hospital visits. However, for patients with"/>
  <result pre="limited extension of the waiting time with administration of antitumor" exact="treatment" post="at the earliest are recommended possible. Professional oncologists must"/>
  <result pre="should also regard the adjustment of chemotherapy regimen rationally. The" exact="treatment" post="strategies should be appropriately adjusted under the guidance of"/>
  <result pre="patients who need further chemotherapy, it is recommended that the" exact="treatment" post="should be carried out under the supervision of an"/>
  <result pre="oncologists online or offline to comprehensively select the appropriate followâ€�up" exact="treatment" post="plans. Management of common adverse events Some lung cancer"/>
  <result pre="events Some lung cancer patients are required to undergo antitumor" exact="treatment" post="such as systemic chemotherapy during the epidemic and deal"/>
  <result pre="under medical guidance: leukocyte count &amp;lt;2.0â€‰Ã—â€‰109/L, neutrophil count &amp;lt;1.0â€‰Ã—â€‰109/L, or" exact="infection" post="symptoms such as fever, frequent urination, and abnormal vaginal"/>
  <result pre="IgM/IgG antibody tests at designated hospitals to rule out COVIDâ€�19" exact="infection" post="from other bacteriological infectious pneumonia or drugâ€�induced lung injury.28"/>
  <result pre="pneumonia or drugâ€�induced lung injury.28 The procedures recommended for SARSâ€�CoVâ€�2" exact="infection" post="screening and distinguished diagnosis are shown in Fig 1."/>
  <result pre="or drugâ€�induced lung injury.28 The procedures recommended for SARSâ€�CoVâ€�2 infection" exact="screening" post="and distinguished diagnosis are shown in Fig 1. The"/>
  <result pre="injury.28 The procedures recommended for SARSâ€�CoVâ€�2 infection screening and distinguished" exact="diagnosis" post="are shown in Fig 1. The next appropriate treatment"/>
  <result pre="distinguished diagnosis are shown in Fig 1. The next appropriate" exact="treatment" post="may be determined according to the causes and comprehensive"/>
  <result pre="situation of the individual patient. Figure 1 Procedures for SARSâ€�CoVâ€�2" exact="infection" post="screening and distinguished diagnosis with lung infiltrative lesions. Psychological"/>
  <result pre="of the individual patient. Figure 1 Procedures for SARSâ€�CoVâ€�2 infection" exact="screening" post="and distinguished diagnosis with lung infiltrative lesions. Psychological management"/>
  <result pre="patient. Figure 1 Procedures for SARSâ€�CoVâ€�2 infection screening and distinguished" exact="diagnosis" post="with lung infiltrative lesions. Psychological management during COVIDâ€�19 The"/>
  <result pre="may worry about COVIDâ€�19 and the impact of delayed antitumor" exact="treatment" post="on their own treatment efficacy, which makes them more"/>
  <result pre="and the impact of delayed antitumor treatment on their own" exact="treatment" post="efficacy, which makes them more predisposed to anxiety, depression,"/>
  <result pre="battle. Here, we provide available recommendations for the alternative transitional" exact="treatment" post="and management of common treatmentâ€�related adverse events for lung"/>
  <result pre="105924.32081636 2JinYH, CaiL, ChengZSet alA rapid advice guideline for the" exact="diagnosis" post="and treatment of 2019 novel coronavirus (2019â€�nCoV) infected pneumonia"/>
  <result pre="CaiL, ChengZSet alA rapid advice guideline for the diagnosis and" exact="treatment" post="of 2019 novel coronavirus (2019â€�nCoV) infected pneumonia (standard version)."/>
  <result pre="6ZhongWZ, WangQ, MaoWMet alGefitinib versus vinorelbine plus cisplatin as adjuvant" exact="treatment" post="for stage IIâ€�IIIA (N1â€�N2) EGFRâ€�mutant NSCLC (ADJUVANT/CTONG1104): A randomised,"/>
  <result pre="JiangZBet alCurrent clinical Progress of PDâ€�1/PDâ€�L1 immunotherapy and potential combination" exact="treatment" post="in nonâ€�small cell lung cancer. Integr Cancer Ther2019; 18:1534735419890020.31838881"/>
  <result pre="XiaL. Coronavirus disease 2019 (COVIDâ€�19): Role of chest CT in" exact="diagnosis" post="and management. Am J Roentgenol2020; 4: 1â€&quot;7. 27DaiWC, ZhangHW,"/>
  <result pre="Roentgenol2020; 4: 1â€&quot;7. 27DaiWC, ZhangHW, YuJet alCT imaging and differential" exact="diagnosis" post="of COVIDâ€�19. Can Assoc Radiol J2020; 4: 846537120913033. 28RubinEJ,"/>
 </snippets>
</snippetsTree>
